SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Moelis & Company (MC) News

Track canonical SquawkNews coverage tagged to MC, Moelis & Company. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol MC Asset equity Sector Markets 90 days 6 Last 68.39 Updated Aug 21, 2026, 04:10 PM UTC Open live news feed
M CAC 40 closes 0.30% higher, led by Stellantis and LVMH The CAC 40 Index rose 26 points, or 0.30%, on Friday to close at 8479, with Stellantis NV, ArcelorMittal and LVMH leading gains. EQUITY | Aug 21, 2026, 04:10 PM UTC L MC Moelis RESULTS: Q2, Q2 Net Income $55.127M, Q2 ADJ REV $409.387M vs. EST $385.5M, Q2 REV $409.387M, Q2 ADJ Net Income $54.076M vs. EST $5 MC Moelis RESULTS: Q2, Q2 Net Income $55.127M, Q2 ADJ REV $409.387M vs. EST $385.5M, Q2 REV $409.387M, Q2 ADJ Net Income $54.076M vs. EST $52.3M, Q2 ADJ EPS $0.63 vs. EST $0.62, Q2 EPS $0.62 EARNINGS | Jul 29, 2026, 08:20 PM UTC H serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - HOOD, VTR, MKL, HLI, MGM, ARMN, NFG, MC, AM, QTWO serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - HOOD, VTR, MKL, HLI, MGM, ARMN, NFG, MC, AM, QTWO, CVI, TDOC, ALKT, MGRC, BBNX, PMT, MAX, LXU, CLB, MDXG, CLMB, FPI, UAN, MFIN, L EARNINGS | Jul 29, 2026, 05:04 PM UTC H Houlihan Lokey Estimates Cut by Morgan Stanley as Sponsor M&A Recovery Lags () -- Investment banking advisory firms are expected to benefit from large corporate M&A activity, though a slower recovery in sponsor-backed deals could weigh on the sector ahead of Q2, Morgan Stanley said in a note on EARNINGS | Jul 09, 2026, 12:34 PM UTC H Moelis cut to Sell at UBS on overly optimistic expectations UBS analyst Michael Brown downgraded Moelis to Sell from Neutral with a price target of $60, up from $58. The firm contends that the stock's risk-reward is increasingly skewed to the downside as consensus expectations fo EARNINGS | Jul 07, 2026, 08:18 PM UTC L Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement Québec is the first province to list (Pr)OKEDI(MC) (ext EQUITY | Jul 06, 2026, 11:00 AM UTC